AU2023217717A1 - Enhanced dna dendrimers and methods of use thereof - Google Patents

Enhanced dna dendrimers and methods of use thereof Download PDF

Info

Publication number
AU2023217717A1
AU2023217717A1 AU2023217717A AU2023217717A AU2023217717A1 AU 2023217717 A1 AU2023217717 A1 AU 2023217717A1 AU 2023217717 A AU2023217717 A AU 2023217717A AU 2023217717 A AU2023217717 A AU 2023217717A AU 2023217717 A1 AU2023217717 A1 AU 2023217717A1
Authority
AU
Australia
Prior art keywords
composition
polynucleotide
cargo
molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023217717A
Other languages
English (en)
Inventor
Samantha Z. Brown
Lori A. Getts
Robert C. Getts
Jennifer M. LUKE
Casey J. Massena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Code Biotherapeutics Inc
Original Assignee
Code Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Code Biotherapeutics Inc filed Critical Code Biotherapeutics Inc
Publication of AU2023217717A1 publication Critical patent/AU2023217717A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2023217717A 2022-02-10 2023-02-09 Enhanced dna dendrimers and methods of use thereof Pending AU2023217717A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308776P 2022-02-10 2022-02-10
US63/308,776 2022-02-10
PCT/US2023/062270 WO2023154788A2 (en) 2022-02-10 2023-02-09 Enhanced dna dendrimers and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2023217717A1 true AU2023217717A1 (en) 2024-08-29

Family

ID=87565106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023217717A Pending AU2023217717A1 (en) 2022-02-10 2023-02-09 Enhanced dna dendrimers and methods of use thereof

Country Status (8)

Country Link
US (1) US20230338557A1 (https=)
EP (1) EP4475891A2 (https=)
JP (1) JP2025507359A (https=)
CN (1) CN119095602A (https=)
AU (1) AU2023217717A1 (https=)
CA (1) CA3243817A1 (https=)
IL (1) IL314724A (https=)
WO (1) WO2023154788A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them
WO2025034978A1 (en) * 2023-08-09 2025-02-13 Code Biotherapeutics, Inc. Enhanced dna dendrimers and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950825B1 (en) * 2013-02-01 2019-09-11 Genisphere, LLC Functionalized dna dendrimers for gene delivery to cells
CN109844134B (zh) * 2016-08-16 2023-05-05 塔驰莱特Ip有限公司 闭合线性dna的生产
KR20220133999A (ko) * 2020-01-31 2022-10-05 타이리스 테라뷰틱스, 에스.엘. 변형된 뉴클레오티드들을 갖는 닫힌 선형 dna
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them

Also Published As

Publication number Publication date
EP4475891A2 (en) 2024-12-18
IL314724A (en) 2024-10-01
JP2025507359A (ja) 2025-03-18
CA3243817A1 (en) 2023-08-17
WO2023154788A3 (en) 2023-11-09
WO2023154788A2 (en) 2023-08-17
CN119095602A (zh) 2024-12-06
US20230338557A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20260048118A1 (en) Compositions and methods for enhancing triplex and nuclease-based gene editing
JP7570107B2 (ja) ドナーオリゴヌクレオチドベースの遺伝子編集を亢進するための組成物および方法
US11779653B2 (en) Multi-armed polyrotaxane platform for protected nucleic acid delivery
KR102873209B1 (ko) 조건부 활성 폴리펩티드 및 이를 제조하는 방법
JP2025511714A (ja) 抗体オリゴヌクレオチドコンジュゲート組成物、およびｄｍｄエクソン４４スキッピングを誘導する方法
JP2025528052A (ja) 脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法
US20230338557A1 (en) Enhanced dna dendrimers and methods of use thereof
WO2024073042A1 (en) Ocular delivery of therapeutic agents
KR20220117091A (ko) 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도
WO2025034978A1 (en) Enhanced dna dendrimers and methods of use thereof
US20230332181A1 (en) Conjugate systems and methods of use thereof
CN113507942A (zh) 分子的细胞内靶向
JP6795492B2 (ja) ＣＬＣＮ７（ＡＤＯ２ ＣＬＣＮ７依存性）遺伝子変異によって引き起こされる常染色体優性大理石骨病２型（ＡＤＯ２）療法のための短鎖干渉ＲＮＡ（ｓｉＲＮＡ）
JP2025538220A (ja) アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
WO2011103215A1 (en) Embedded chimeric peptide nucleic acids and use thereof
JP2025537167A (ja) カルシウム電位開口型チャネル補助サブユニットガンマ１（ｃａｃｎｇ１）結合タンパク質及び骨格筋へのｃａｃｎｇ１媒介送達
KR20250009410A (ko) 범용 서프레서 tRNA 및 이의 용도
WO2025038901A1 (en) Cyclic peptides for delivering therapeutics
CN116940680A (zh) 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
HK40055666A (en) Intracellular targeting of molecules